炎症和解决方案编程的髓状回路控制了表皮和介质细胞三阴性乳腺癌的治疗耐药性
Liqun Yu1, Charlotte Rivas1, Fengshuo Liu1
1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, United States of America.
The Journal of clinical investigation
|February 17, 2026
概括
三阴性乳腺癌表现出多样化的巨细胞群,阻碍了治疗的有效性. 针对共享的上游调节器提供了一个潜在的策略,通过调节炎症和解决途径来克服治疗耐药性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种具有有限治疗选择的侵袭性亚型.
- 瘤微环境,特别是巨细胞等免疫细胞,在治疗反应和耐药性方面发挥着关键作用.
- 了解巨细胞异质性对于开发TNBC中新的治疗策略至关重要.
研究的目的:
- 研究人类三阴性乳腺癌中巨细胞种群的异质性.
- 阐明促炎性和促溶解性巨细胞在治疗耐药性的不同作用.
- 确定潜在的治疗点,以克服TNBC中治疗耐药性.
主要方法:
- 人类乳腺癌瘤的单细胞RNA测序.
- 分析巨细胞表型和局部化在上皮状和中状瘤中的分析.
- 利用小鼠模型来总结观察到的模式和测试治疗干预措施.
- 研究了脂肪酸代谢 (ω-3和 ω-6) 和C1q在免疫抑制中的作用.
主要成果:
- 确定了两个不同的巨细胞子集:亲炎性和亲解决性,两者都在治疗阻断性瘤中积累.
- 证明了这些子集之间的反相关性,表明相互排斥的阻力机制.
- 观察到不同的局部化模式:在上皮类瘤中的炎症性巨细胞和在中细胞类瘤中的亲解析性巨细胞.
- 表明巨细胞分泌的C1q对抗T细胞功能,而 ω-6脂肪酸通路有助于表皮状瘤的免疫抑制.
- 通过中性粒细胞和巨细胞介导的ELOVL5敲击减轻免疫抑制.
结论:
- 由不同的巨细胞轴驱动的失调的炎症和解决方案破坏了TNBC中治疗诱导的免疫监测.
- 亲分辨的巨细胞通过 ω-3 吸收和分辨蛋白的产生促进阻力,在类似中瘤的瘤中.
- 炎症性巨细胞和中性粒细胞通过表皮状瘤中的 ω-6 途径促进抵抗.
- 针对这些独特的炎症轴的共享上游调节器是克服治疗耐药性的有希望的策略.
相关概念视频
Inflammatory Response
17.2K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.2K
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Metastasis
6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K


